Adhesion of Children and Adolescents Treated for Cancer to Personalized Support in Adapted Physical Activity Program
Condition(s) studied
Investigational drug(s) / intervention(s)
questionnaires: human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study. Questionnaire administred before the start of current care APA programm and after 4 to 6 months.
PedsQL quality of life questionnaires: validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
Study summary
Adapted physical activity session with a formed professional is proposed in standard care since 2022 in the immuno-hematological service to all children with newly diagnosed cancer or relapse.
The aim of this study is to keep the children in the APA programm during all the treatment lenght.
This study aims to evaluate by questionnaires the motivation keys and restraint from children and parents before the APA program starts (at diagnosis or relapse if not previously participating to an APA programm) and after 4 to 6 months of APA programm.
The final expected fallout is to enhance children adhesion to long term APA program by implementing tools in current practice to overcome restraints from young patients and their parents
Eligibility
Primary outcome measure(s)
- Adhesion to an APA programm — 4 to 6 months
Adherence of children and adolescents undergoing cancer treatment to personalized support in Adapted Physical Activity \[APA\] offered at an early stage and for a minimum duration of 4 to 6 months : patients following the whole APA program/patients included, in percent
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU Grenoble Alpes | Grenoble | ISERE |
More University Hospital, Grenoble trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06230016 on ClinicalTrials.gov ↗ ← All trials in France